A clinical study of Norfloxacin in chronic paranasal sinusitis

Abstract

Norfloxacin (NFLX) was administered 600mg/day t. i. d. to 37 patients with acute paranasal sinusitis (APS) and acute exacerbation of paranasal sinusitis (AECPS). The clinical efficacy was evaluated for 16 cases with APS and 21 cases with AECPS. The following results were obtained: (1) The overall efficacy rate (cases of excellent and good responses as judged by the attending physician) was 62.2% of all patients, 56.3% for and 67.7% for AECPS.(2) The overall efficacy rate, as judged by committee, was 70.3%. The efficacy rate was 50.0% for APS and 85.7% for AECPS.(3) The bacteriological efficacy rate was 53.4% (including both bacteria eliminated and bacteria exchanged). The efficacy rate was 40.0% for APS, and 66.7% for AECPS.(4) The improvement rate was determined by X-ray findings for 19 cases. The rate of excellent and good results was 36.8%, and that of excellent, good and moderate results was 68.4%. These two rates were 25.0% and 75.0%, respectively for APS and 40.0% and 66.7% respectively for AECPS.(5) Side effects were observed in 1 of the 37 cases (2.7%). No abnormal laboratory findings were observed. From these results, NFLX is judged to be a useful drug in the treatment of paranasal sinusitis.